• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Noxafil (posaconazole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Noxafil (posaconazole)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Noxafil (posaconazole) is a triazole antifungal agent. It blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of the enzyme lanosterol 14a-demethylase and accumulation of methylated sterol precursors.

    Noxafil is specifically indicated for the prophylaxis of invasive Aspergillus and Candida infections in subjects, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised.

    Noxafil is supplied as a 4-ounce (123 mL) suspension designed for oral administration. The recommended initial dose of the drug is 200 mg (5 mL) three times a day with a full meal.

    Clinical Results

    FDA approval
    FDA approval of Noxafil was based on the results of two clinical trials.

    Study 1 This randomized, double-blind trial compared 200 mg of posaconazole oral suspension, given three times a day, with 400 mg of fluconazole, given once a day, as prophylaxis against invasive fungal infections in allogeneic hematopoietic stem cell transplant (HSCT) recipients with Graft versus Host Disease (GVHD). Treatment duration was 80 days for posaconazole and 77 days for fluconazole. The primary endpoint was efficacy, evaluated using a composite endpoint of proven/probable invasive fungal infections, death, or treatment with systemic anti-fungal therapy. In this study the clinical failure rate of posaconazole (33%) was similar to fluconazole (37%). Cause mortality was similar at 16 weeks for the posaconazole group (19%) and the fluconazole group (20%).

    Study 2 This was a randomized, open-label study that compared 200 mg of posaconazole oral suspension (three times a day), with 400 mg of fluconazole suspension (once daily) or 200 mg itraconazole oral solution (twice a day), as prophylaxis against IFIs in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes. Subjects were assessed for 107 days post-treatment. The primary endpoint was the same as study 1. In this study clinical failure was lower for patients treated with posaconazole (27%) when compared to patients treated with fluconazole or itraconazole (42%). Cause mortality was lower at 100 days for the posaconazole treated group (14%) versus the fluconazole and itraconazole groups (21%).

    In both study groups subjects receiving posaconazole prophylaxis experienced substantially lower breakthrough infections caused by Aspergillus species when compared to subjects receiving fluconazole or itraconazole.

    Ongoing Study Commitments

    • Schering has agreed to a deferred pediatric study under PREA for prophylaxis of invasive fungal infections in pediatric patients ages zero months to twelve years of age who are at high risk for developing these infections.
      Final Report Submission: September 15, 2011
    • Schering has agreed to a post approval study to be conducted among patients receiving antifungal prophylaxis. The study will enroll patients who are at risk for low absorption. Different dosing strategies including the use of therapeutic drug monitoring to increase plasma concentrations will be explored.
      Protocol Submission: by January 2007
      Study Start: by January 2008
      Final Report Submission: by March 2011

    Side Effects

    Adverse reactions associated with the use of Noxafil may include, but are not limited to, the following:

    • fever
    • hypokalemia
    • thrombocytopenia
    • anemia
    • diarrhea
    • nausea
    • insomnia
    • abdominal pain
    • coughing

    In addition, Noxafil has been associated with prolongation of the QT interval on the electrocardiogram. It should be administered with caution to patients with potentially proarrhythmic conditions and should not be administered with drugs that are known to prolong the QTc interval and are metabolized through CYP3A4.

    Mechanism of Action

    Noxafil is a triazole antifungal agent. It blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of the enzyme lanosterol 14a-demethylase and accumulation of methylated sterol precursors.

    Literature References

    Notheis G, Tarani L, Costantino F, Jansson A, Rosenecker J, Friederici D, Belohradsky BH, Reinhardt D, Seger R, Schweinitz DV, Wintergerst U Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006;49 Suppl 1:37-41.

    Groll AH, Walsh TJ Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006;49 Suppl 1:7-16.

    Dodds Ashley ES, Alexander BD Posaconazole. Drugs of today 2005 Jun;41(6):393-400.

    Carrillo-Munoz AJ, Quindos G, Ruesga M, Alonso R, del Valle O, Hernandez-Molina JM, McNicholas P, Loebenberg D, Santos P Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. The Journal of antimicrobial chemotherapy 2005 Mar;55(3):317-9. Epub 2005 Feb 10.

    Courtney R, Pai S, Laughlin M, Lim J, Batra V Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrobial Agents and Chemotherapy 2003 Sep;47(9):2788-95.

    Additional Information

    For additional information regarding Noxafil or fungal infections, please vist the Schering web page.

    Company Name: Schering-Plough
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing